ArticleOncogene2021
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER
Open access · greenAbstract read
In one paragraph
Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Integrated analyses reveal a potential role for PFKFB4 in M2 macrophage polarization and hepatocellular carcinoma progression.Cancer cell international · 2026Article
- Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation.NPJ breast cancer · 2026Article
- Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells.Cancer letters · 2026Article
- The PELP1 Pathway and Its Importance in Cancer Treatment.Biomolecules · 2025Review
- Proline-, Glutamic Acid-, Leucine-Rich Protein 1 (PELP1): Diversity, Structural Conservation, and Evolutionary Origins Across the Species.International journal of molecular sciences · 2025Article
- Targeting phosphofructokinase 2 the isoform PFKFB4 suppresses glioblastoma proliferation and malignancy.Genes & genomics · 2025Article
- Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context ofbioRxiv : the preprint server for biology · 2025Article
- Emerging Mechanisms of Therapy Resistance in Metastatic ER+ Breast Cancer.Endocrinology · 2025Review
- Isoform-Specific Gene Regulation by Progesterone Receptors Drives Divergent Phenotypes in Breast Cancer Cells.bioRxiv : the preprint server for biology · 2025Article
- Warburg effect and lactylation in cancer: mechanisms for chemoresistance.Molecular medicine (Cambridge, Mass.) · 2025Review
- Research progress and application status of organoid in breast cancer subtypes.Biomolecules & biomedicine · 2025Review
- The role and therapeutic potential of glucose metabolism in multidrug resistance of cancer.Frontiers in cell and developmental biology · 2025Review
- PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma.Cancer research communications · 2024Article
- PFKFB3 facilitates cell proliferation and migration in anaplastic thyroid carcinoma via the WNT/β-catenin signaling pathway.Endocrine · 2024Article
- Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.Viruses · 2024Article
- Article
- Function of Steroid Receptor Coactivators in T Cells and Cancers: Implications for Cancer Immunotherapy.Critical reviews in immunology · 2024Review
- Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target.Cancers · 2023Review
- Differential roles of highly expressed PFKFB4 in colon adenocarcinoma patients.Scientific reports · 2023Article
- Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Thu H TruongMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0003-2394-551X
Elizabeth A BennerMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Kyla M HagenMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Nuri A TemizMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Carlos Perez KerkvlietMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0003-2530-840X
Ying WangMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-9052-0023
Emilio Cortes-SanchezDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.
Chieh-Hsiang YangDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.
Marygrace C TrousdellCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Thomas PengoUniversity of Minnesota Informatics Institute, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-9632-918X
Katrin P GuillenDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.
Bryan E WelmDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-1879-6612
Camila O Dos SantosCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Sucheta TelangJames Graham Brown Cancer Center, Department of Medicine (Division of Medical Oncology and Hematology), University of Louisville, Louisville, KY, USA.
Carol A Lange *Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. lange047@umn.edu.ORCID http://orcid.org/0000-0003-2751-3976
Julie H Ostrander *Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. hans1354@umn.edu.ORCID http://orcid.org/0000-0002-5038-6875
University of Minnesota Medical Center · USUniversity of Minnesota · USUniversity of Utah · USCold Spring Harbor Laboratory · USUniversity of Louisville · US
Funding
Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9MUniversity of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0MTRAINING-PULMONARY CELL &MOLECULAR BIOLOGY &PHYSIOLOGYT32HL007741 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI DUDLEY, R. ADAMS, INGBAR, DAVID H · 1994 to 2023
$13.9MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis, Gabor T Marth · 2017 to 2026
$13.5MTRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3MProgesterone Receptor (PR) Signaling Cross Talk Drives ER+ Breast CancerR01CA229697 · NCI · UNIVERSITY OF MINNESOTA · PI Carol A Lange, Douglas Yee · 2020 to 2026
$3.6MSRC-3/PELP1 complexes drive stem-like phenotypes in luminal breast cancerR01CA236948 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A, OSTRANDER, JULIE H · 2020 to 2024
$2.4MProbing the role of epigenomics in Brca1-deficient mammary tumors.R01CA248158 · NCI · COLD SPRING HARBOR LABORATORY · PI DOS SANTOS, CAMILA · 2020 to 2024
$2.2MDefining the cellular and molecular effects of aging and age of pregnancy on breast tissue homeostasis and cancer initiationR01AG069727 · NIA · COLD SPRING HARBOR LABORATORY · PI DOS SANTOS, CAMILA · 2020 to 2024
$1.8MProgestin and growth factor cross-talk in breast cancerR01CA123763 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A · 2006 to 2010
$1.1MPELP1 mislocalization favors hormone-induced breast cancer developmentF32CA210340 · NCI · UNIVERSITY OF MINNESOTA · PI TRUONG, THU HA · 2017 to 2019
$147kNCATS NIH HHS UL1 TR000114NCI NIH HHS F32 CA210340NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA123763NCI NIH HHS R01 CA229697NCI NIH HHS R01 CA236948NCI NIH HHS R01 CA248158NCI NIH HHS T32 CA009138NCI NIH HHS U54 CA224076NHLBI NIH HHS T32 HL007741NIA NIH HHS R01 AG069727
Abstract
Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER
Indexed as
AnimalsBreastBreast NeoplasmsCell Line, TumorCo-Repressor ProteinsDrug Resistance, NeoplasmEstrogensFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiceNeoplastic Stem CellsNuclear Receptor Coactivator 3PaclitaxelPhosphofructokinase-2Co-Repressor ProteinsEstrogensNCOA3 protein, humanNuclear Receptor Coactivator 3PaclitaxelPELP1 protein, humanPhosphofructokinase-2Receptors, EstrogenTamoxifenTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.